CIK 0001841387
- Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522214851
- Phone
- +1 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,160,783
- in 1 filing, $3.2M under 10b5-1 plans
Net −$3,160,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-11 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −59,379 | $10.46 | $621K | 113,321 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Exercise or conversion 10b5-1 | +125,000 | $1.55 | $194K | 393,566 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −220,866 | $11.50 | $2.5M | 172,700 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −125,000 | 1,638,968 | ||
| 2026-01-26 | Tak Paul Peter Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +629,000 | 629,000 | ||
| 2025-06-25 | Tak Paul Peter Chief Executive Officer | Grant or award | +42,826 | $4.67 | $200K | 268,566 |
| 2025-03-19 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −400 | $9.00 | $4K | 225,740 |
| 2025-03-18 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −25,772 | $8.77 | $226K | 226,140 |
| 2025-02-12 | Tak Paul Peter Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +525,000 | 525,000 | ||
| 2025-01-15 | Tak Paul Peter Chief Executive Officer | Sale | −21,704 | $7.23 | $157K | 251,912 |
| 2025-01-08 | Tak Paul Peter Chief Executive Officer | Sale | −21,172 | $8.22 | $174K | 273,616 |
| 2024-11-29 | Tak Paul Peter Chief Executive Officer | Sale | −48,847 | $4.56 | $223K | 294,788 |
| 2024-11-21 | Tak Paul Peter Chief Executive Officer | Exercise or conversion | +12,900 | $1.55 | $20K | 343,635 |
| 2024-11-21 | Tak Paul Peter Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −12,900 | 1,763,968 | ||
| 2024-07-17 | Tak Paul Peter Chief Executive Officer | Sale | −22,528 | $6.47 | $146K | 330,735 |
| 2024-07-11 | Tak Paul Peter Chief Executive Officer | Sale | −20,293 | $5.97 | $121K | 353,263 |
| 2023-11-28 | Tak Paul Peter Chief Executive Officer | Shares withheld for taxes | −43,443 | $0.90 | $39K | 373,556 |
| 2023-11-26 | Tak Paul Peter Chief Executive Officer | Grant or award | +180,108 | 416,999 | ||
| 2023-04-28 | Tak Paul Peter Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2022-12-09 | Tak Paul Peter Chief Executive Officer | Purchase | +12,935 | $1.92 | $25K | 40,985 |
Page 1 of 2 · 24 trades